<DOC>
	<DOC>NCT00969046</DOC>
	<brief_summary>This study is exploring different administration schedules (short versus prolonged infusion) to optimize the safety and efficacy profile of EPO906A (patupilone) in patients with pretreated advanced colon cancer.</brief_summary>
	<brief_title>Dose-Escalation Study in Advanced Colon Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>1. Histologically confirmed, locally advanced, progressive or metastatic colon cancer, up to 4 prior lines of prior chemotherapy, at least one measurable lesion according to RECIST 2. Age ≥ 18 years 3. Life expectancy ≥ 12 weeks 4. WHO performance status of 01 5. Negative serum pregnancy test 6. Adequate hepatic or renal function and hematological parameters 1. Brain metastases 2. Ileostomy or colonostomy 3. History of pelvic radiotherapy 4. Grade &gt; 1 diarrhea at baseline Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Colon cancer</keyword>
	<keyword>MTD</keyword>
	<keyword>DLT</keyword>
	<keyword>EPO906</keyword>
	<keyword>patupilone</keyword>
</DOC>